1 study found for:    15340416 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated
Has Results
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Condition: Melanoma
Interventions: Biological: ALVAC-MART-1 vaccine;   Biological: MART-1:26-35(27L) peptide vaccine;   Biological: Aldesleukin;   Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes;   Biological: incomplete Freund's adjuvant

Indicates status has not been verified in more than two years